Reviewing Pluri (NASDAQ:PLUR) and Apollomics (NASDAQ:APLM)

Pluri (NASDAQ:PLUR) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.

Valuation & Earnings

This table compares Pluri and Apollomics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34 million	17.84	-$22.58 million	($4.53)	-0.49
Apollomics	$8.50 million	5.38	-$10.94 million	N/A	N/A

Apollomics has higher revenue and earnings than Pluri.

Volatility and Risk

Pluri has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Apollomics has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.

Institutional & Insider Ownership

16.6% of Pluri shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 43.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pluri and Apollomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Apollomics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings for Pluri and Apollomics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1	0	0	0	1.00
Apollomics	1	0	0	0	1.00

Summary

Apollomics beats Pluri on 6 of the 8 factors compared between the two stocks.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

About Apollomics

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company’s pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.